Painful PR

U.S. Food and Drug Administration reviewer David Graham told Congress that "at least five medications now sold to consumers pose such risks that their sale should be limited or stopped." They are the weight-loss drug Meridia, anti-cholesterol drug Crestor, acne drug Accutane, painkiller Bextra and asthma treatment Serevent. Pfizer just retained Ogilvy PR for its "pain franchise," which includes Bextra and Celebrex. "Pfizer's pain franchise has been subject to the same inquiries as Merck's Vioxx," reports PR Week. "Pfizer has already undertaken an advertising initiative for Celebrex to promote its safety."